Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00112736 · ClinicalTrials.gov registry record · Phase 1

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

A Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
69
Enrollment target
8
Study locations

NCT00112736 is a Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 69 participants, above the 39-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (77% higher). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00112736, a Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
69 participants
Enrollment target
8
Study locations

Study Summary

Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurrent malignant glioma.

Conditions Studied

Adult Glioblastoma Adult Giant Cell Glioblastoma Adult Gliosarcoma Adult Anaplastic Astrocytoma Adult Anaplastic Oligodendroglioma Adult Mixed Glioma Adult Diffuse Astrocytoma Adult Pilocytic Astrocytoma Adult Pineal Gland Astrocytoma Adult Subependymal Giant Cell Astrocytoma

Interventions

  • OTHER laboratory biomarker analysis
  • PROCEDURE therapeutic conventional surgery
  • OTHER pharmacological study
  • DRUG erlotinib
  • DRUG temsirolimus

Study Locations (8)

California

  • University of California Los Angeles - Los Angeles
  • University of California San Francisco - San Francisco

Texas

  • M D Anderson Cancer Center - Houston
  • University of Texas Health Science Center - San Antonio

Maryland

  • National Cancer Institute Neuro-Oncology Branch - Bethesda

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Wisconsin

  • University of Wisconsin Hospital and Clinics - Madison

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2005-04
Est. Completion 2014-04
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00112736

The ClinicalTrials.gov registry entry for NCT00112736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 39-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (77% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT00112736 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Texas, Maryland.

Frequently Asked Questions

What is clinical trial NCT00112736 about?

NCT00112736 is a clinical study titled "Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma". Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with erlotinib and to see how well they work in treating patients with recurr...

What is the current status of trial NCT00112736?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2005-04. Estimated completion is 2014-04.

What conditions does trial NCT00112736 study?

This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma.

What interventions are being tested in trial NCT00112736?

The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic conventional surgery (PROCEDURE), pharmacological study (OTHER), erlotinib (DRUG), temsirolimus (DRUG).

Who is sponsoring clinical trial NCT00112736?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00112736 being conducted?

This trial has 8 study locations across California, Maryland, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adult Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Adult Glioblastoma

All registered trials for this condition

Adult Giant Cell Glioblastoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.